SCLCs and LCNECs are sensitive to PARP inhibition in vitro.

Slides:

Advertisements

Similar presentations

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

Advertisements

CDK2 is highly expressed in colon cancer cells and curcumin selectively suppresses HCT116 cell proliferation. CDK2 is highly expressed in colon cancer.

Key differences in protein expression and pathway activation between SCLCs and NSCLCs. A, for each cell line, protein lysates were collected and analyzed.

IL-1β differentially regulates CXCL5 and CXCL8 protein secretion in NHTBE and NSCLC cells. IL-1β differentially regulates CXCL5 and CXCL8 protein secretion.

سرطان الثدي Breast Cancer

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

C. Allison Stewart, Lauren Averett Byers Cancer Cell

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

AKT dependence of ovarian cancer cell lines.

Bortezomib sensitivity correlates with basal NF-κB activity in KP lung adenocarcinoma cell lines. Bortezomib sensitivity correlates with basal NF-κB activity.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

nab-Paclitaxel targets the tumor epithelial cells.

A20 inhibits caspase-8 cleavage and TRAIL-induced apoptosis.

C. Allison Stewart, Lauren Averett Byers Cancer Cell

An siRNA screen identifies BER pathway members as sensitizers to temozolomide (TMZ) in pediatric GBM. A and B, SJG2 and KNS42 cells were transfected with.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.

TDP1 knockdown increases the sensitivity of rhabdomyosarcoma cell lines to CPT treatment. TDP1 knockdown increases the sensitivity of rhabdomyosarcoma.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

eIF5A-PEAK1 signaling regulates KRAS protein expression.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

JAK3A572V mutation causes constitutive JAK3 activity and IL-2–independent proliferation of NKTCL cells. JAK3A572V mutation causes constitutive JAK3 activity.

A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =

Thiocolchicoside suppresses cell proliferation and colony formation of various cancer cell lines. Thiocolchicoside suppresses cell proliferation and colony.

The sesquiterpene lactone PN up-regulates MDM2 and p53 proteins.

Inhibition of lung cancer cell proliferation and viability by CYT387.

Effects of knockdown of DDR1 levels on proliferation and apoptosis.

PTENP1 sensitizes renal cancer cells to chemotherapy.

G3139 substitutes for heparin, which is required for the biological activity of FGF2. G3139 substitutes for heparin, which is required for the biological.

Radiosensitization by combined Wee1 and PARP inhibition.

Inhibition of stress-associated MAPK signaling attenuates SASP expression in CAFs. A, N-CAFs were treated with 100 nmol/L GEM plus DMSO or the above-listed.

Sensor siRNAs can be used in high-order combinations.

The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle distribution. The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle.

Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases. Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases.

Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.

TFAP2A knockdown inhibits cell growth by targeting HIF-1α signaling.

The cross-talk between PARylation and phosphorylation.

N-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. n-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. HEC-1-A.

Model of ATM-MPG–mediated therapeutic resistance in pGBM.

Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma cells. Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma.

Synergistic cytotoxicity of 17AAG and TNF treatment in human lung cancer cell lines. Synergistic cytotoxicity of 17AAG and TNF treatment in human lung.

Drug interaction signatures for GIST and benign osteoma cell lines representing all combinatorial data compiled in a 9 × 9 drug matrix. Drug interaction.

Combined inhibition of Wee1 and PARP causes persistent radiation-induced DNA damage. Combined inhibition of Wee1 and PARP causes persistent radiation-induced.

CLIC1 supports invadopodia formation in vitro and metastasis in vivo.

NKT cell recognition of CD1d1 molecules is inhibited by treatment with ascites. NKT cell recognition of CD1d1 molecules is inhibited by treatment with.

WP1066 inhibits the progression of OCIM2 cells through the cell cycle.

Knockdown of ERBB3, NRG1, or ERBB2 in H358-TwistER cells reduces basal PI3K–AKT signaling and ablates serum-independent proliferation before EMT. A and.

AS1411 alters subcellular distribution of PRMT5 in a time-dependent, dose-dependent, and nucleolin-dependent manner. AS1411 alters subcellular distribution.

The effects of AZD1775 and olaparib on DNA damage response signaling.

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

Functional SLC6A3 in ccRCC cell lines KMRC3 and SNU-349, but not in conventional cell lines. Functional SLC6A3 in ccRCC cell lines KMRC3 and SNU-349, but.

Although equivalent experimental systems have been employed in a variety of assessments to determine BCR-ABL1 kinase domain mutation sensitivity on the.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

Effect of MIF siRNA on the production of MMP-13 induced by LPA

Establishment of HeLa/rtTAA/TRE-N1-IC cell line.

Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105. Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105.

MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.

Wild-type and oncogenic Ras differentially regulate cell proliferation

mRNA expression of PARP1 in SCLC cell lines and solid tumors.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

Inhibition of BCR-mediated signaling by ARQ 531.

miR-181a knockdown inhibits VEGF and MMP1 secretion in vitro.

MEK1/2-ERK1/2-p190RHOGAP and INK4a/ARF deficiency drive RHOA activation in NSCLC. A and B, G-LISA assay showing RHOA-GTP levels in H460, A549, and H838.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.

Presentation transcript:

SCLCs and LCNECs are sensitive to PARP inhibition in vitro. SCLCs and LCNECs are sensitive to PARP inhibition in vitro. A, cells were treated with 0.1, 1, and 10 μmol/L AZD2281 for 24 hours, cell extracts collected, and PAR levels evaluated by ELISA to assess PARP1 activity. B, IC50 values for lung cancer cell lines treated with AZD2281 for 5 days. C, lung and breast cancer cells were treated with increasing concentrations of AZD2281 or AG014699 for 14 days. D, PARP1 and EZH2 knockdown by siRNA affect SCLC proliferation. Lauren Averett Byers et al. Cancer Discovery 2012;2:798-811 ©2012 by American Association for Cancer Research